thought us
jack tool kit could elabor nih us genom sequenc
project
trivia question scale term genom sequenc per year genom
center requir achiev order particip us initi
recent note report track start
amid healthi end market reiter equal weight tool dx takeaway
lab director tool time industri expert call proprietari novaseq
survey say elast upgrad ow takeaway
review rais expect detail show import progress
consist result new surpris reiter equal weight
genesight survey say psych like get paid critic
barclay geograph end market tracker agil pmi tracker
q/q pmi tracker q/q pmi
tracker q/q thermo fisher pmi tracker
q/q water pmi tracker q/q
w/w chines yuan flat w/w japanes yen strengthen w/w
hot topic week myriad present full dataset random
control trial rct genesight posit recept market share
past week charl river syneo health close
earn season comment healthi trend
biopharma end market post strong beat rel rais
expect revenu expect cash
ep
coverag univers finish week sinc last thursday tool
diagnost lab comparison
week russel nasdaq composit
stat week proprietari novaseq survey custom expect
upcom event tool time industri expert confer call seri
tool dx focus top debat coverag featur dialogu
top industri expert specif seri includ kol discuss bioproduct
gener sequenc perspect lab director
ob/gyn oncologist psychiatrist plastic surgeon dermatologist use
diagnost healthcar devic
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
pleas present barclay life scienc tool diagnost trivia question
week week ask question tool diagnost industri
would prefer dont look answer wont polic simpl answer
next week weekli
trivia question scale term genom sequenc per year genom center
requir achiev order particip us initi
last week answer almost genet test current market
jack tool kit life scienc tool diagnost
week answer question receiv client tri pick
topic respons dont pick question keep tri get
question could elabor nih us genom sequenc
project
may nation enrol open us project million
genom sequenc nih-l initi receiv billion fund
period centuri cure act sequenc current expect begin
end particip recruit span year enrol
open anyon live unit state age far us
enrol volunt beta version children current unabl enrol
though nih contempl chang guidelin allow particip
main focu recruit effort includ minor project
often underrepres biomed research fact nih host event
specif commun across countri attract volunt divers background
dataset gener initi de-identifi broadli access
medic research sampl taken volunt must share electron health
record answer question regard lifestyl project conduct
clia regul manner enabl particip access data addit volunt
contact import mutat identifi data secur privaci major
focu nih project core data set store secur cloud
access encrypt channel
overal expect signific beneficiari numer large-
scale genom sequenc project us expect sequenc ramp
sever year around human genom sequenc year
project recent confer call dr niall lennon senior director translat
genom product develop broad institut note broad institut
hope one genom center includ project nih expect
genom sequenc site year project number
scale year bring total annual sequenc least
nih would prefer whole genom sequenc perform sampl dr
lennon note genotyp array could also use order reduc cost nih
look genom center scale annual sampl order
particip project full recap convers dr lennon
landscap pleas see note takeaway broad
current expect timelin roll-out includ
juli applic due genom center wish particip
septemb award decis regard particip genom center
expect septemb data gener begin end
year end data gener sequenc begin initi
us one numer larg sequenc project appear
ramp other includ uk genom project well similar initi
franc recent receiv million fund similarli chines precis
medicin initi pmi plan total fund estim billion
billion number commerci compani also engag large-scal sequenc
project regeneron plan sequenc exom biobank sampl
month period similarli grail initi call sequenc genom
year period estim us initi requir novaseq
complet gener around annual consum revenu
given expect annual sequenc ramp genom assum
vast major sequenc take place year span individu novaseq
cost around million averag genom scale cost around
sequenc impli consum revenu scale thought
pleas see novaseq survey proprietari
novaseq survey say elast upgrad ow
us illumina opportun
section summar recent research public pleas contact us
copi
track may
mettler toledo result essenti line expect believ
put compani squar track expect mettler toledo deliv
constant currenc growth organ growth quarter growth ex-fx
lab segment off-set organ declin industri end market due
challeng comp y/i importantli lab industri end market
appear remain healthi level addit china continu import
market grow quarter expect demand
china remain solid put compani posit continu drive growth
overal compani mettler toledo rais ep guidanc modestli account
quarterli beat fx compani continu show solid result compound
growth tuck-in buy-back remain valuat sensit share trade
ev/ebitda reiter equal weight rate
bruker corp start amid healthi end market reiter
start strong note capit healthi end market dynam
deliv top bottom line beat revenu million grew y/i beat
estim upsid quarter driven combin better organ
growth favor fx encourag
achiev organ upsid quarter continu strength nano
solid trend calid mass spectrometri across clinic life scienc applic
ep beat quarter better model line revenu beat
margin expans limit fx headwind quarter constant currenc
basi margin expand continu improv effici busi
maintain guidanc emb organ growth healthi level
margin improv lead low-teen ep growth despit beat view
reiter guidanc prudent given back half heavi natur revenu
earn believ share trade discount peer properli reflect
modest organ growth expect compani depend
cyclic instrument sale reiter equal weight rate
tool dx takeaway lab director tool time industri expert call
thursday host confer call two industri expert discuss diagnost
platform current laboratori oper environ discuss focus
current oper strategi reimburs chang consider invest
lab molecular diagnost includ platform oper
environ hospit system increasingli focus drive effici
consolid test standard system platform pama clearli
concern laboratori industri cut describ huge posit
lab director see opportun genetics/genom tout recent invest
low cost provid laboratori test believ labcorp quest best
posit reimburs dynam clinic laboratori broader healthcar
inc proprietari novaseq survey say elast
upgrad ow may
believ proprietari novaseq custom survey provid answer critic
question thesi critic time substanti elast demand
custom adopt novaseq system provid visibl
multipl year double-digit growth better convict durabl
revenu growth upgrad overweight ew rais
price target
takeaway broad institut tool time industri expert call
monday host confer call dr niall lennon senior director
translat genom product develop broad institut discuss
experi illumina novaseq platform well import area
gener sequenc landscap discuss focus novaseq
us project long-read technolog current landscap clinic
novaseq dr lennon discuss reason adopt platform well
elast demand given cheaper price sequenc broadli volum increas
partial driven larg initi us project million
whole genom sequenc dr lennon expect nih award genom center
busi septemb data gener end year long-read
technolog dr lennon note number compani shown earli success
though sequenc remain expens inaccur high level adopt
clinic cmss nation decis panel expect drive higher level
adopt technolog expect import growth driver
myriad report solid result highlight across hereditari cancer test
hct new product believ well receiv ultim believ
payor coverag continu matter thesi order drive leverag
profit revenu beat estim midpoint guidanc
view conserv head print ep came better
expect due effect cost manag relat elev program
hct franchis drove quarterli revenu beat revenu declin y/i due
continu price pressur volum growth achiev target believ move
part off-set quarter headwind weather off-set equal size
benefit cdx test metastat breast cancer myriad also note riskscor
drive growth prevent channel encourag believ sentiment
around hct franchis remain mute price headwind stabil estim
quarter genesight revenu technic miss forecast declin
q/q compani attribut higher privat payor mix amid record
volum myriad tout full result rct present meet
attend last night confirm posit data point remiss respons
novemb top line result prolari benefit recent medicar coverag
expans favor intermedi risk patient higher new pama rate show
strong sequenti improv million revenu
encourag see solid quarter posit physician feedback genesight rct
present continu believ thesi depend expand reimburs
coverag new product limit visibl drive equal weight rate
report provid in-depth review bureau labor statist bl march
metropolitan area employ unemploy summari inform
releas monthli bl provid updat employ situat
counti unit state use data method track employ condit
underli market labcorp quest patient servic center psc psc
import sourc revenu gener two nation laboratori
repres approxim revenu employ growth one driver lab
util impact health insur rate employ screen
believ report provid use method track underli econom
perform compani region footprint base model counti
analysi look county-level psc locat match
employ data specif county-specif model creat weight psc
concentr bl employ data counti lab oper pleas let
us know would like addit data comprehens
corp rais expect detail show import
deliv strong start revenu
expect cash ep magnitud upsid nice
see though entir surpris given signific flu season remind quidel
rais expect march industri confer includ barclay global
healthcar confer confirm higher trajectori april analyst day
said flu revenu still came well revis guidanc
believ major share gain beneficiari fda reclassif rapid
influenza test platform drove lower-qu competitor market
continu believ gain momentum success recent flu
season yield annuiti year come ye success flu season creat
challeng comp though view short-sight
instal base sofia instrument y/i custom
contract creat sticki consum stream forese futur quidel
execut sofia menu expans allow greater util per
syneo health inc consist result new surpris reiter
result syneo health appear consist recent messag
compani investor focu softer clinic book adopt
guidanc good news new concern pop
compani continu progress merger inc research inventiv
revenu million line previou guidanc
million though forecast million follow solid
net book-to-bil compani peer syneo result appear
slower start manag comment thing pick toward end
onward believ speak health end market despit weaker
revenu cash ep better expect driven
lower tax rate model compani guid share count
million buyback march believ sentiment weak syneo
quarterli result appear close enough expect reiter equal
weight rate believ key compani show turn better growth
work reduc leverag quarter
inc genesight survey say psych like get
paid critic may
thought myriad genesight rct present american psychiatr
associ annual meet genesight hit two tougher endpoint
studi tie remiss respons demonstr test clinic effect
rct miss primari endpoint achiev statist signific
improv symptom design studi shed light one inher problem
limit genesight clinic util uncommon patient alreadi take
appropri medic patient red therapi complet
dataset suggest patient
genesight guid arm continu show
improv week believ test deliv real valu physician
patient payor said think price scrutin
myriad present full dataset random control trial rct genesight
posit recept market share past week
charl river syneo health close earn season
comment healthi trend biopharma end market
post strong beat rel rais expect
revenu expect cash ep
help investor gaug end market activ develop barclay pmi
tracker tracker repres weighted-averag growth agil
thermo fisher underli geographi use pmi data ism
unit state markit intern one-quart lag barclay agil
thermo fisher pmi tracker
correl organ growth follow quarter
barclay agil pmi tracker regist q/q
approxim agil revenu gener outsid unit state
exposur asia europ compani barclay agil pmi end
market tracker one-quart lead correl compani organ
growth rate notic trend agil geograph exposur
growth past quarter far back intern data track
believ pmi tracker best use one-quart lead indic
expansionari tracker perform start year give us good convict
agil abil hit guidanc organ growth
barclay mettler toledo pmi tracker regist q/q
approxim compani revenu gener outsid unit state
signific exposur europ china barclay mettler toledo
pmi end market tracker one-quart lead correl compani
organ growth rate notic trend mettler toledo geograph
exposur growth past quarter far back intern data
track believ pmi tracker best use one-quart lead indic
note strong recent pmi result improv visibl solid growth
barclay pmi tracker regist q/q
approxim compani revenu gener outsid unit state
signific exposur emerg market barclay perkinelm pmi end market
tracker one-quart lead correl compani organ growth
rate notic trend geograph exposur growth
past quarter far back intern data track believ
pmi tracker best use one-quart lead indic note better
pmi perform support perkinelm guidanc impli acceler
barclay thermo fisher pmi tracker regist q/q
approxim thermo fisher revenu gener outsid unit state
exposur china revenu germani uk amongst
other barclay thermo fisher end market tracker one-quart lead
correl compani organ growth rate optic notic
trend thermo fisher geograph exposur growth past quarter
far back intern data track believ pmi tracker best use
one-quart lead indic note solid recent pmi tracker
perform similar thermo fisher organ growth guidanc
barclay water pmi tracker regist q/q
approxim revenu gener outsid unit state
exposur europ revenu asia amongst other barclay
water end market tracker one-quart lead correl
compani organ growth rate optic notic trend
water geograph exposur growth past quarter far back
intern data track believ pmi tracker best use one-
pmi tracker
perform similar expect organ growth
indic note expansionari read
vi price perform valuat updat
coverag univers finish week sinc last thursday tool
diagnost lab comparison
week russel nasdaq composit
best perform stock group follow
contrast acceler diagnost worst perform stock
broadli speak week posit stock increas
stock decreas current level enterpris valu tool trade
ebitda diagnost trade lab trade
enterpris valu life scienc tool compani trade near twelv
month ntm ebitda estim rang
compar five year averag ntm ebitda ten year averag
ntm ebitda past five year group broadli trade within rang
forward ebitda
enterpris valu diagnost compani trade near twelv month
ntm ebitda estim rang
compar five-year averag ntm ebitda ten-year averag
ntm ebitda past five year group broadli trade within rang
forward ebitda
enterpris valu cro compani trade near twelv month ntm
ebitda estim rang syneo health icon
compar five-year averag ntm ebitda ten-year averag
ntm ebitda past five year group broadli trade within rang
forward ebitda
enterpris valu lab compani trade near twelv month ntm
ebitda estim compar five-year averag ntm ebitda ten-
year averag ntm ebitda past five year group broadli trade
within rang forward ebitda
vii metric coverag univers
price target base multipl ebitda estim materi discuss valuat methodolog avail upon request full disclosur
cover compani includ detail company-specif valuat methodolog risk pleas refer http //publicresearch barcap com
note barclay research estim ghdx iclr lh prxl
remaind consensu
note barclay research estim ghdx iclr lh prxl
remaind consensu
note barclay research estim ghdx iclr lh prxl
remaind consensu
viii stat week
proprietari novaseq survey custom expect novaseq
ix week life scienc tool diagnost
section present news summari relev articl
icon sponsor industry-wid clinic trial survey support transform trial
initi tuesday icon announc result new survey pharmaceut
execut profession icon pharma intellig examin key
challeng declin research develop effici challeng
frequent cite survey respond patient enrol site start-up
regulatori approv delay chang respond also identifi studi start
patient recruit retent protocol develop three key area
potenti gener save effici
pleas reach us barclay sale repres sign-up
tool time industri expert confer call seri tool dx
pleas join us tool time seri industri expert confer call span
breadth coverag includ life scienc tool diagnost clinic lab
call focu sever top debat coverag featur
dialogu top industri expert specif seri includ kol discuss
life scienc tool categori bioproduct gener sequenc cro
trend earli develop perspect lab director ob/gyn oncologist
psychiatrist plastic surgeon dermatologist use diagnost healthcar
devic time avail end call investor hope
join us
 et ob/gyn perspect diagnost gyn surgic medic
 et oncologist perspect cancer diagnost post-asco
dial-in detail everi confer call
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
author contribut research report research analyst unless otherwis indic
public date top report reflect local time report produc may differ releas date provid
gmt
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis barclay research depart
oper independ absa research depart absa research produc absa bank limit act corpor
invest bank divis part barclay africa group limit affili invest bank barclay bank plc elig
client may receiv research report research depart may reach differ conclus may contain differ
conflict forecast recommend trade idea
price sourc thomson reuter last avail close price relev trade market unless anoth time sourc
